The Senate Judiciary Committee has cleared four bills intended to address the high prices of prescription drugs by prohibiting practices that delay the launch of generic products. The bills now go to the Senate floor where they have a chance of passage given recent actions by the Biden Administration, the US Federal Trade Commission, and bipartisan interest in drug pricing.
Versions of the bills – which address so-called pay-for-delay deals, product hopping, citizen petitions to the US Food and Drug Administration, and pharmacy benefit managers – were introduced in the previous Congress
